• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

    9.650 -0.030 (-0.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ocular Therapeutix, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Why Ocular Therapeutix (OCUL) Stock Is Nosediving
    What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report... 
    Via StockStory
    Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗
    Via Chartmill
    News headline image
    Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
    Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year... 
    Via StockStory
    News headline image
    Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
    Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo... 
    Via StockStory
    News headline image
    1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
    Via StockStory
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    1 Cash-Heavy Stock to Research Further and 2 We Brush Off
    Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
    Via StockStory
    News headline image
    3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
    Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was... 
    Via StockStory
    News headline image
    3 Stocks Under $10 We Think Twice About
    Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi... 
    Via StockStory
    News headline image
    Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
    As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Small-Cap Stocks We’re Skeptical Of
    Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
    Via StockStory
    News headline image
    3 of Wall Street’s Favorite Stocks We’re Skeptical Of
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
    Via StockStory
    News headline image
    Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why
    Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about... 
    Via StockStory
    Topics Economy Stocks
    News headline image
    1 Russell 2000 Stock Worth Investigating and 2 We Avoid
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
    Via StockStory
    News headline image
    1 Volatile Stock for Long-Term Investors and 2 Facing Challenges
    A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
    Via StockStory
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
    Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗
    Wall Street has grown increasingly optimistic ahead of the readout, with analysts pointing to a potential blockbuster opportunity in wet AMD. 
    Via Stocktwits
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
    In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
    Via MarketMinute
    News headline image
    Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
    The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
    Via MarketMinute
    News headline image
    Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
    Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 22.4% year on year to $13.25 million. Its... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack
    The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Ocular Therapeutix... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Cash-Burning Stocks We’re Skeptical Of
    Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
    Via StockStory
    Topics Bankruptcy
    News headline image
    1 Healthcare Stock to Consider Right Now and 2 We Find Risky
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
    Via StockStory
    Topics Stocks
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗
    French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre. 
    Via Stocktwits
    News headline image
    3 Reasons OCUL is Risky and 1 Stock to Buy Instead
    Over the last six months, Ocular Therapeutix’s shares have sunk to $10.44, producing a disappointing 7.4% loss - a stark contrast to the S&P 500’s 11.3% gain. This might have investors contemplating... 
    Via StockStory
    Topics Bankruptcy Stocks
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.